Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Two-year Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity

NCT03693430 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT03693430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03693430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Two-year Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
October 5, 2018
Completion date
March 23, 2021
Enrollment
304 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight